Another study of patients with CP class A and advanced HCC receiving antiangiogenic therapy revealed that low serum IGF-1 levels (<63.6 ng/mL) reduced the progression-free and overall survival rates (17). Here, IGF1 is linked to hepatocellular carcinoma.